0001658021-26-000006.txt : 20260423 0001658021-26-000006.hdr.sgml : 20260423 20260423122728 ACCESSION NUMBER: 0001658021-26-000006 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260423 DATE AS OF CHANGE: 20260423 EFFECTIVENESS DATE: 20260423 FILER: COMPANY DATA: COMPANY CONFORMED NAME: General Oncology, Inc. CENTRAL INDEX KEY: 0001658021 ORGANIZATION NAME: EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-581608 FILM NUMBER: 26886986 BUSINESS ADDRESS: STREET 1: 202 WASHINGTON STREET, SUITE 318 CITY: BROOKLINE STATE: MA ZIP: 02445 BUSINESS PHONE: 617-468-4646 MAIL ADDRESS: STREET 1: 202 WASHINGTON STREET, SUITE 318 CITY: BROOKLINE STATE: MA ZIP: 02445 D 1 primary_doc.xml X0708 D LIVE 0001658021 General Oncology, Inc. 57 Chapel Street, Third Floor Newton MA MASSACHUSETTS 02458 617-468-4646 DELAWARE None None Corporation true Jeffrey Aaron Glazier c/o General Oncology, Inc. 57 Chapel Street, Third Floor Newton MA MASSACHUSETTS 02458 Executive Officer Director Arnold Glazier c/o General Oncology, Inc. 57 Chapel Street, Third Floor Newton MA MASSACHUSETTS 02458 Executive Officer Director Abid Ansari c/o General Oncology, Inc. 57 Chapel Street, Third Floor Newton MA MASSACHUSETTS 02458 Executive Officer Michael J. Petit c/o General Oncology, Inc. 57 Chapel Street, Third Floor Newton MA MASSACHUSETTS 02458 Director Barry Seeman c/o General Oncology, Inc. 57 Chapel Street, Third Floor Newton MA MASSACHUSETTS 02458 Director Pharmaceuticals Decline to Disclose 06b false 2026-04-15 false true true Simple Agreement for Future Equity (SAFE), the shares of Issuer capital stock into which the SAFE may convert (SAFE Shares), and the shares of Issuer capital stock into which the SAFE Shares may convert. false 0 4805299 4805299 0 false 37 0 0 0 Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees or to related entities to those listed in Item 3. false General Oncology, Inc. Jeffrey Aaron Glazier Jeffrey Aaron Glazier Chief Executive Officer 2026-04-23